Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163266 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
NCT01163266 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 462 participants.
The verdict
NCT01163266, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
Interventions
- DRUG Placebo
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163266
The ClinicalTrials.gov registry entry for NCT01163266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01163266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163266 about?
NCT01163266 is a clinical study titled "Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder". The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
What is the current status of trial NCT01163266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2010-07. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01163266?
The interventions under investigation include: Placebo (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT01163266?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.